Overview

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Status:
Not yet recruiting

Trial end date:
2024-10-17

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory non-small cell lung cancer and breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Second Affiliated Hospital of Soochow University

Treatments:

Immune Checkpoint Inhibitors
Vinorelbine